Dealmaker’s Diary: Beyond the Famous Brand Lives an Even Better Investment
This Latin American bottling giant has tripled since 2020 while implementing AI across operations yet trades at just 14.8x earnings with minimal tariff risk.
Buy This, Not That: Why This Banking Powerhouse Belongs in Your Portfolio
Despite both posting strong earnings, JPMorgan Chase outperforms Goldman Sachs on nearly every metric, making it the clear choice for investors.
Monday Takeaways: The Untold Story Behind Last Week’s Panic
Markets struggle to find footing after historic crash. With Powell speaking Wednesday and China GDP dropping, this week could determine 2025’s direction.
Dealmaker’s Diary: The Bigger the Dip, the Juicier the Chip
Elevance is trading at a deep discount with low volatility and strong fundamentals giving investors a rare shot at big value with lower risk.
Dealmaker’s Diary: Why This Rapid Correction Could Mean Rapid Returns
This correction happened at the fifth fastest pace ever. But history shows that 86% of the time, markets are higher one year after such events.
Buy This, Not That: QQQs Will Lead the Bounce When Trade Wars Cool
When comparing potential recoveries the QQQs will bounce higher and faster thanks to big tech fundamentals even despite falling harder than the Russell 2000.
Dealmaker’s Diary: The 12-Month Money Move That Could Double Your Portfolio
Big money flips stocks yearly now, not every decade. By using the same timeline, we’ve generated 27% returns while others hold deteriorating positions.
Buy This, Not That: Copper Profits From Tariff Tears
With Trump announcing tariffs today, one surprising copper giant offers triple the profit margins and pays you 6.9% to watch the drama unfold.
Monday Takeaways: What to Expect With the April 2 Tariff Deadline
Monday Takeaways: What to Expect With the April 2 Tariff Deadline
Dealmaker’s Diary: The Rare Disease Fighter Trading at Bargain Prices
This biotech generates positive cash flow while others burn money. At 25x forward earnings, you’re getting tomorrow’s genetic breakthroughs at a discount.